Ice-plant cream to prevent chemotherapy-related hand–foot syndrome

MS-N159 · Botanical topical care · Hand–foot syndrome prevention · Breast cancer · Randomized feasibility pilot · Appraised 28 October 2026

Can Mesembryanthemum crystallinum (ice-plant) cream prevent hand–foot syndrome during doxorubicin- or docetaxel-containing breast-cancer chemotherapy?

Evidence at a glance

Evidence label: Feasible for completers; efficacy not established
Benefit: The 13-person pilot met adherence, retention and acceptability targets among enrolled participants, but it was designed primarily to test feasibility and was far too small to establish prevention.
Certainty: Very low. Only 13 of 58 eligible patients enrolled; 6 received cream plus standard care and 7 received standard care alone.
Risk: Minor transient erythema or warmth occurred in two participants. Product allergy, broken skin and infection require caution.

What was studied

Participants applied a branded ice-plant intensive cream thinly to palms and soles three times daily from the first chemotherapy day through seven days after the final cycle, alongside standard advice and 5–10% urea cream. The control group received standard care alone. NCT05755646 prespecified feasibility as the primary outcome.

What the evidence found

Recruitment failed: 13 of a planned 36 participants were randomized. Twelve completed all visits; all five intervention completers met the adherence definition and 83% reported high satisfaction. Hand–foot symptoms were generally mild in both groups, and the investigators reported no relevant between-group difference. The study cannot tell us whether the cream prevents clinically important hand–foot syndrome.

How to interpret it

This is a feasibility result, not an efficacy trial. The intervention combined the study cream with standard preventive care, the groups were tiny and unblinded, and cooling practices differed. It says nothing about tumor response, recurrence or survival.

Practical safety context

Do not apply an unfamiliar botanical cream to infected, ulcerated or severely inflamed skin without review. Stop for new burning, swelling, blistering or rash and contact the oncology team. The studied branded formulation cannot be assumed equivalent to homemade or differently formulated ice-plant products.

Questions for the care team

Is this exact formulation available, and are its ingredients compatible with my skin and other topical products?
What evidence-based hand–foot prevention is already part of my regimen?
Which symptoms should trigger treatment interruption or urgent assessment?

Funding and conflicts

WALA Heilmittel GmbH, the manufacturer of the studied product, funded personnel, materials and operations. The authors stated that the funder had no role in design, analysis, interpretation or publication and declared no conflicting commercial relationship.

Sources

Last literature search: 28 October 2026. Record appraisal: 28 October 2026. This page is educational and does not replace individualized medical advice. Symptom, biomarker or observational findings must not be interpreted as proof of tumor control, recurrence prevention or longer survival unless those outcomes were directly tested.